Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
somatropin + rosiglitazone
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
Somatropin + rosiglitazone is a combination therapy that has been studied for treating HIV-associated abdominal obesity and insulin resistance. Somatropin (recombinant human growth hormone) reduces visceral adipose tissue (VAT) but can worsen glucose homeostasis, while rosiglitazone, a thiazolidinedione, improves insulin sensitivity. When combined, rosiglitazone abrogates the adverse effects of somatropin on insulin sensitivity and glucose tolerance while maintaining somatropin's beneficial effect on reducing visceral fat.
- Other names
- recombinant human growth hormone + rosiglitazonerhGH + rosiglitazone
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)GHR (Growth hormone receptor)
Beyond the preview
Go deeper on somatropin + rosiglitazone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on somatropin + rosiglitazone.